oncotype DX
Pronunciation: ON-ko-type D-X
A genomic assay that analyzes gene expression to predict chemotherapy benefit and recurrence risk in breast cancer.
Full Definition
Oncotype DX is a commercially available genomic test that analyzes the expression of 21 genes in hormone receptor-positive, HER2-negative breast cancer tissue to generate a Recurrence Score (RS). This score predicts both the likelihood of distant recurrence and the potential benefit from adjuvant chemotherapy. The test helps oncologists and patients make informed treatment decisions by identifying patients who may safely avoid chemotherapy without compromising outcomes. The Oncotype DX assay has been validated in large clinical trials and is widely used in clinical practice to guide adjuvant treatment decisions in early-stage breast cancer.
Usage
Usage note: Always capitalize as a proprietary test name and include the Recurrence Score when available.
In Context
- "The Oncotype DX Recurrence Score was 18, indicating intermediate risk." — Genomic testing report
- "Based on the low Oncotype DX score, chemotherapy was omitted from treatment." — Treatment decision documentation